GlassScriptPhysician profile
Mark Franklin Naylor
NPI 1518916386
$3,021.20
in general payments reported to CMS, 2019-2025
22 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $335 · 2022: $1,112 · 2023: $1,063 · 2024: $116 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.77 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.76 | 2021-2025 | |
| Pfizer INC. | $481.58 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $264.64 | 2019-2023 | Sotyktu |
| Amgen INC. | $188.67 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $175.40 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $164.43 | 2021-2024 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $113.52 | 2023 | Adbry |
| Merz North America, INC. | $100.14 | 2021 | |
| Lilly USA, LLC | $97.44 | 2022-2023 | Taltz, Olumiant |
| Genzyme Corporation | $73.98 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $49.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.38 | 2023-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $26.79 | 2024 | |
| Organogenesis INC. | $22.64 | 2023 | Puraply |
| Sandoz INC. | $19.63 | 2023 | Hyrimoz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $19.47 | 2023 | Cimzia |
| Organon LLC | $18.29 | 2025 | Vtama |
| Biofrontera INC. | $18.11 | 2022 | |
| Incyte Corporation | $16.81 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $14.06 | 2022 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
| Journey Medical Corporation | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.